Published in final edited form as:

Tetrahedron Lett. 2013 September 18; 54(38): 5211–5213. doi:10.1016/j.tetlet.2013.07.067.

Efficient synthesis of *cis*-2,6-di-(2-quinolyl)piperidine)

Derong Ding¹, Linda P. Dwoskin¹, and Peter A. Crooks^{2,*}

¹Department of Pharmaceutical Science, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA

²Department of Pharmaceutical Science, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA

Abstract

An efficient synthesis of *cis*-2,6-di-(2-quinolyl)piperidine) has been developed. The key steps involve Wittig reaction of *N*-Cbz-protected *cis*-piperidine-2,6-dicarboxaldehyde (**3**) with 2-(triphenylphosphinyl-methyl)quinoline bromide (**4**) and sequential removal of the *N*-Cbz group and double bond reduction. This synthetic procedure provides an efficient preparation for this useful norlobelane analogue.

Keywords

Lobelane; *cis*-2,6-di-(2-quinolyl)piperidine); norlobelane analogues; Wittig reaction; Swern oxidation; quinlobelane

1. Introduction

Lobelane (*N*-methyl-*cis*-2,6-diphenethylpiperidine, Figure 1), a minor piperidine alkaloid of *Lobelia inflata*¹, has been shown to exhibit good affinity and selectivity for the tetrabenazine (TBZ) binding site on the vesicular monoamine transporter (VMAT2), and is also a potent inhibitor of vesicular dopamine uptake.² Structure-activity relationship (SAR) studies indicate that lobelane analogues lacking the *N*-methyl substituent (i.e. norlobelane analogues) retain their affinity for the TBZ binding site on VMAT2, suggesting that the presence of the *N*-methyl group is not critical for interaction with VMAT2. Furthermore, other studies have shown that norlobelane is a potent inhibitor of [³H]DA uptake into striatal vesicles (*K*_i = 43 nM)². SAR studies have also shown that the phenyl moieties in lobelane can be replaced with 1-naphthyl or 2-naphthyl groups, resulting in analogues that are potent and selective inhibitors of VMAT2^{2a}. However, such analogues have poor water-solubility and poor drug-like properties. Recent studies have shown that lobelane analogues in which the phenyl moieties have been replaced with heterocyclic rings, such as pyridyl, quinolyl or indolyl, have improved water-solubility (Figure 1). Only the quinolyl analogues retained potent VMAT2 inhibitory properties,³ with quinlobelane (Figure 1) exhibiting potent inhibition of vesicular [³HDA] uptake (*K*_i = 51 nM). However, the synthetic procedures utilized in this study were not amenable to the synthesis of 2-quinolyl analogues of

© 2013 Elsevier Ltd. All rights reserved.

*Corresponding author. Tel.: +501-686-6495; fax: +001501-686-6057; pacrooks@uams.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

norlobelane [e.g. *cis*-2,6-di-(2-quinolyl)piperidine]; compound **1**, Scheme 1] and its analogues. In order to obtain more drug-like 2-quinolyl analogues of both norlobelane and lobelane for studying both structure-activity and structure-property relationships, a new and efficient synthesis of *cis*-2,6-di-(2-quinolyl)piperidine is now reported, which may be useful for the general synthesis of a wide range of compounds of this type.

2. Results and Discussion

We now report a versatile and efficient method for the preparation of 2-quinolynorlobelane. Our retrosynthetic approach is outlined in scheme 1, and is centered around a Wittig reaction for the construction of two double bonds sequentially. The requisite precursor **3** (Scheme 1) can be synthesized from commercial pyridine-2,6-dicarboxylic acid.

The synthesis of target molecule **1** was executed as shown in scheme 2. Pyridine-2,6-dicarboxylic acid was heated under reflux in methanol containing a few drops of concentrated H₂SO₄ to form the sulfate salt **5**. Reduction of **5** under 50 psi H₂ pressure followed by crystallization of the crude product from hexane provided the pure *cis*-isomer **6** in 91% yield,⁴ which was then protected as its *N*-Cbz derivative **7**. In our original plan, we utilized DIBAL-H for the reduction of **7**, in the hope of obtaining aldehyde **3** in one step. Unfortunately, an unidentified mixture was obtained after work-up of the reaction. To obtain the key intermediate **2**, we reduced ester **7** with LiBH₄ to afford alcohol **8**. Then, we explored Dess-Martin periodinane and PCC reactions in our attempts to oxidize compound **8** to the key intermediate **3**. However, only complex mixtures were obtained, which may have been due to facile decomposition of aldehyde **3** during purification by column chromatography. We subsequently found that alcohol **8** could be oxidized efficiently to **3** under Swern conditions.⁵ In the Wittig reaction of **3** with compound **4** (Scheme 3), which is the pivotal step in the synthesis of **1**, we found that it was advantageous to utilize the crude aldehyde **3** directly without further purification to afford the optimal yield of **2** (it is noteworthy that all attempts to obtain a pure sample of compound **3** failed). In our initial attempts to synthesize **2**, THF was used as solvent and *n*-BuLi was utilized as base, and the product was isolated in 6% yield in the two-step procedure. In order to optimize the reaction conditions, other bases were evaluated. The yields obtained by substituting *n*-BuLi with either LiHMDS, NaHMDS, or NaOEt were 8%, 10% and 11%, respectively, for the two-step synthetic procedure. To our satisfaction, when *tert*-BuOK was used as base, the yield of **2** improved significantly to 51% for the two step reaction.

With the key compound **2** in hand, our initial strategy was to synthesize compound **1** from **2** in one step by removal of the *N*-Cbz group followed by double bond hydrogenation over 20% Pd(OH)₂. However, when this procedure was followed, TLC analysis indicated a complex mixture, which proved difficult to purify by column chromatography.

A similar outcome was observed when 10% Pd/C was used. We speculated that these problems might be due to hydrogenolytic ring opening of the piperidine ring under the reduction conditions utilized. In order to circumvent this problem, a strategy involving two separate steps was employed. First, we attempted to reduce the double bonds utilizing Wilkinson's catalysis⁶ prior to removal of the *N*-Cbz group; however, no reaction occurred, and the starting material was recovered. Subsequently, we turned to a second strategy, and attempted the removal of the *N*-Cbz group of **2** followed by double bond reduction. We found that 6N HCl at reflux could be used to deprotect the *N*-Cbz group affording compound **9** in quantitative yield. Hydrogenation of **9** to the desired compound **1** was achieved utilizing 10% Pd/C as catalyst in 75% yield.

Scheme 3 provides the synthetic route to phosphonium salt **4**, which was utilized in the Wittig reaction of compound **3** to **2** (Scheme 2). 2-Methylquinoline was oxidized by SeO₂ at high temperature (170 °C) under solvent-free conditions to afford aldehyde **10** in good yield. It should be noted that when this oxidation reaction was performed in high boiling point solvents such as 1,4-dioxane, the yield was very low, even after prolonged reaction times. Aldehyde **10** could be reduced by NaBH₄ in EtOH to afford carbinol **11** in 92% yield, followed by bromination of **11** in 33% HBr/AcOH to afford bromide **12** in high yield⁷ (we found that when compound **10** was brominated with 48% aq. HBr, the yield of **12** was only 72% and the reaction required a long time for completion). Compound **12** was then heated under reflux with triphenyl phosphine (PPh₃) in toluene to obtain the desired compound **4** in 95% yield.

In conclusion, an efficient method for the preparation of *cis*-2,6-di-(2-quinolyl)piperidine (**1**) has been developed. The key step in the synthetic scheme is the introduction of the two 2-quinolyl moieties via Wittig reaction with *N*-Cbz-protected *cis*piperidine-2,6-dicarboxaldehyde. Other quinolyl analogues of norlobelane and lobeline are currently being prepared utilizing this synthetic procedure, and their biological evaluation is underway.

Acknowledgments

The authors gratefully acknowledge support from NIH grant U01 DA13519. The University of Kentucky holds patents on lobeline and the analogues described in the current work. A potential royalty stream to LPD and PAC may occur consistent with University of Kentucky policy.

References and notes

- Wieland H, Schopf C, Hermesen W. *Liebigs Ann. Chem.* 1925; 444:40–68.
- (a) Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, Crooks PA. *J. Med. Chem.* 2005; 48:5551–5560. [PubMed: 16107155] (b) Zheng G, Dwoskin LP, Deaciuc AG, Crooks PA. *Bioorg. Med. Chem. Lett.* 2008; 18:6509–6512. [PubMed: 18976906]
- Vartak AP, Deaciuc AG, Dwoskin LP, Crooks PA. *Bioorg. Med. Chem. Lett.* 2010; 20:3584–3587. [PubMed: 20494575]
- Robert C, Michael D. J. *Org. Chem.* 1996; 61:3332–3341.
- Harry HW, Karen R, Roman K. *Tetrahedron Lett.* 1989; 30:6077–6080.
- Baldwin JE, Adlington RM, Jones RH, Schofield CJ, Zaracostas C. *Tetrahedron.* 1986; 42:4879–4888.
- Markus S, Gebhard H. *Eur. J. Org. Chem.* 2009; 26:4458–4467.
- The spectroscopic data of all known compounds are identical to the reported data. All new compounds were characterized by ¹H NMR, ¹³C NMR and high resolution mass spectrometry (HRMS). Selected data (NMR spectra were recorded in CDCl₃, ¹H at 300 MHz and ¹³C at 75 MHz): (i) Compound **2**: colorless oil; ¹H NMR: δ 7.91 (d, 2H, *J*=8.4Hz), 7.78 (d, 2H, *J*=7.5), 7.68–7.60 (m, 4H), 7.48–7.25 (m, 9H), 6.86 (dd, *J*=16.2Hz, 2H), 6.82 (dd, *J*=16.2Hz, 2H), 5.24 (s, 2H), 5.21 (s, 2H), 2.13–1.84 (m, 5H), 1.68–1.63 (m, 1H) *ppm*; ¹³C NMR: δ 155.9, 155.8, 148.1, 137.6, 136.8, 136.2, 131.5, 129.6, 129.4, 128.7, 128.3, 128.2, 127.6, 127.4, 126.2, 119.3, 67.8, 52.2, 28.5, 15.6 *ppm*; HRMS (EI) Calcd. for C₃₅H₃₁N₃O₂, 525.2416; Found 525.2419 (ii) Compound **9**: viscous oil; ¹H NMR: δ 8.10–8.01 (m, 4H), 7.77–7.65 (m, 4H), 7.58–7.45 (m, 4H), 7.26–6.86 (m, 4H), 3.60–3.55 (m, 2H), 2.04–1.86 (m, 3H), 1.63–1.43 (m, 3H); ¹³C NMR: δ 156.0, 148.2, 139.3, 136.5, 130.8, 129.8, 129.4, 127.6, 127.5, 126.3, 119.0, 59.2, 32.1, 24.7; HRMS(EI) Calcd. for C₂₇H₂₅N₃ 391.2048; Found 391.2045 (iii) Compound **1**: viscous oil; ¹H NMR: δ 8.08–7.99 (m, 4H), 7.76–7.79 (m, 2H), 7.62–7.68 (m, 2H), 7.50–7.45 (m, 2H), 7.32–7.26 (m, 2H), 3.11–3.06 (m, 4H), 2.61–2.57 (m, 2H), 2.02–1.94 (m, 4H), 1.78–1.71 (m, 3H), 1.27–1.19 (m, 3H); ¹³C NMR: δ 162.5, 148.0, 136.6, 129.6, 128.9, 127.7, 126.9, 125.9, 121.6, 56.8, 37.0, 35.9, 32.4, 24.8; HRMS(EI) Calcd. for C₂₇H₂₉N₃ 395.2361; Found 395.2367.

Figure 1.
Structures of lobelane, heterocyclic analogs of lobelane and quinlobelane

Scheme 2.

Synthetic route to compound **1**. Reagents and conditions: (a) Conc. H_2SO_4 , MeOH, reflux, 71% ; (b) 10% Pd/C, H_2O , RT, 91%; (c) CbzCl, DIPEA, THF, RT, quant; (d) LiBH_4 , THF, $0^\circ\text{C} \rightarrow \text{RT}$, 81%; (e) Swern oxidation, -78°C ; (f) **4**, *tert*-BuOK, THF, RT, 51 % (two steps); (g) 6N HCl, reflux, quant; (h) 10% Pd/C, RT, 75%.

Scheme 3.

Synthetic route to compound **4**. Reagents and conditions: (a) SeO_2 , solvent-free, $170\text{ }^\circ\text{C}$, 81%; (b) NaBH_4 , EtOH, RT, 92%; (c) 33% HBr/AcOH, reflux, 98%; (d) PPh_3 , toluene, reflux, 95%.